Association of Phenotypic Age and Antibody Titers Among SARS-Co-V2 Infected Patients and Vaccinated Groups

Study Overview
=================
Brief Summary
-----------------
Defining the antibody response to SARS-CoV-2 will be essential for understanding disease progression, long-term immunity, and vaccine efficacy. Investigators designed a study investigating the neutralizing antibody response among post-infected and post-vaccinated individuals to determine how the spike protein neutralizing antibody correlates with natural infection and vaccination and how mutations of viral strains affect associated antibodies. New Taipei City Municipal TuCheng Hospital established a special infectious pneumonia ward in May 2021 to treat patients infected with symptomatic SARS-CoV-2 patients. During the period, 97 patients were admitted and enrolled. In light of the current timing of the pandemic, most published serological studies are predominantly cross-sectional or, at most, include a longitudinal follow-up. Cognitive function and PhenoAgeAccel will be examined for SARS-CoV-2 N and S titers decline trend analysis to correlate long-COVID brain fog or early decline of N and S antibodies.Therefore, investigators designed a three-year longitudinal study to detect patients' SARS-CoV-2 neutralizing and spike antibodies.

Detailed Description
-----------------
Coronaviruses are a diverse group of viruses infecting many different animals, and th can cause mild to severe respiratory infections in humans. At the end of 2019, a novel coronavirus designated as SARS-CoV-2 emerged in Wuhan, China, and caused an outbreak of unusual viral pneumonia. Being highly transmissible, this novel coronavirus disease, also known as coronavirus disease 2019 (COVID-19), has spread fast worldwide. It has overwhelmingly surpassed SARS and MERS regarding both the number of infected people and the spatial range of epidemic areas. The ongoing outbreak of COVID-19 has posed an extraordinary threat to global public health. Studies in large cohorts of SARS-CoV-2 infected individuals indicate that antibodies to the receptor-binding domain (RBD) of the viral spike glycoprotein appear within the first three weeks from symptoms onset, and IgG and/or IgA seroconversion occurs either sequentially or simultaneously with the appearance of IgM. Studies showed anti-RBD IgG in 95% of COVID-19 patients by the fourth week from symptom onset and observed that these antibodies increased throughout follow-up until the third-month post-hospital discharge. Moreover, the early presence of anti-RBD IgG and anti-spike IgA positively correlated with patient survival and reduced persistence of SARS-CoV-2 RNA in nasopharyngeal swabs, respectively. The spike glycoprotein mediates entry into target cells via the ACE2 receptor. Clinical trials with monoclonal antibodies (mAbs) against its RBD decreased viral load in patients with recently diagnosed mild/moderate COVID-19. Furthermore, anti-spike neutralizing antibodies (nAbs) produced by COVID-19 patients can block viral infection of human cells in vitro and counter viral replication in vivo. However, the impact of nAbs on the COVID-19 course is still controversial, with some studies even suggesting either a detrimental role for nAbs in disease progression or finding no nAbs differences among hospitalized patients who subsequently experienced varying disease outcomes. Whether SARS-CoV-2 nAbs decline at a similar pace is yet to be conclusively established. Defining the antibody response to SARS-CoV-2 will be essential for understanding disease progression, long-term immunity, and vaccine efficacy. Investigators designed a study investigating the neutralizing antibody response among post-infected and post-vaccinated individuals to determine how the spike protein neutralizing antibody correlates with natural infection and vaccination and how mutations of viral strains affect associated antibodies. New Taipei City Municipal TuCheng Hospital established a special infectious pneumonia ward in May 2021 to treat patients infected with symptomatic SARS-CoV-2 patients. During the period, 97 patients were admitted and enrolled. In light of the current timing of the pandemic, most published serological studies are predominantly cross-sectional or, at most, include a longitudinal follow-up. Cognitive function and PhenoAgeAccel will be examined for SARS-CoV-2 N and S titers decline trend analysis to correlate long-COVID brain fog or early decline of N and S antibodies. Therefore, investigators designed a three-year longitudinal study to detect participantss' SARS-CoV-2 neutralizing and spike antibodies.

Official Title
-----------------
Association of Phenotypic Age and Antibody Titers Among SARS-Co-V2 Infected Patients and Vaccinated Groups

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Other: Covid19 Vaccination dose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 20 yrs Evidenced COVID-19 infeciton by PCR sequening or commercial IVD rapid test kits. (stratified by infection periods, before 2022 vs. in 2022) Clealry understand the study protocol, blood drawing, organ function survey, phenoage and phenoageAccel exams and cognitive functional evaluation. Agree with regular follow-up as the protocol designs Exclusion Criteria: Refuse any blood draw or follow-up schedule Refuse at any time The PIs judges that the patient is no longer suitable to continue the study follow-up Death

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| SARS-CoV-2 Infection<br>Participants from individuals with SARS-CoV-2 Infection . | Other: Covid19 Vaccination dose<br>* Participants above or below 2 dose Covid19 Vaccination<br>|
| SARS-CoV-2 non-infection with vaccination<br>Participants after the second dose covid19 vaccination from individuals without SARS-CoV-2 infection. | Other: Covid19 Vaccination dose<br>* Participants above or below 2 dose Covid19 Vaccination<br>|
| SARS-CoV-2 non-infection without vaccination<br>Participants get covid19 vaccination below 2 dose from individuals without SARS-CoV-2 infection. | Other: Covid19 Vaccination dose<br>* Participants above or below 2 dose Covid19 Vaccination<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SARS COVID N Ab trends among different subgroups | Participants' SARS-CoV-2 neutralizing antibody measure among different subgroups | baseline | 
| SARS COVID N Ab trends among different subgroups | Participants' SARS-CoV-2 neutralizing antibody measure among different subgroups | 3 month | 
| SARS COVID N Ab trends among different subgroups | Participants' SARS-CoV-2 neutralizing antibody measure among different subgroups | 6 month | 
| SARS COVID N Ab trends among different subgroups | Participants' SARS-CoV-2 neutralizing antibody measure among different subgroups | 9 month | 
| SARS COVID N Ab trends among different subgroups | Participants' SARS-CoV-2 neutralizing antibody measure among different subgroups | 12 month | 
| SARS COVID S Ab trends among different subgroups | Participants' SARS-CoV-2 neutralizing antibody measure among different subgroups | baseline | 
| SARS COVID S Ab trends among different subgroups | Participants' SARS-CoV-2 neutralizing antibody measure among different subgroups | 3 month | 
| SARS COVID S Ab trends among different subgroups | Participants' SARS-CoV-2 neutralizing antibody measure among different subgroups | 6 month | 
| SARS COVID S Ab trends among different subgroups | Participants' SARS-CoV-2 neutralizing antibody measure among different subgroups | 9 month | 
| SARS COVID S Ab trends among different subgroups | Participants' SARS-CoV-2 neutralizing antibody measure among different subgroups | 12 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SARS COVID N Ab trends among different baseline PhenoAge scores | Hematology measure associated with PhenoAge scores | baseline | 
| SARS COVID N Ab trends among different baseline PhenoAge scores | Hematology measure associated with PhenoAge scores | 3 month | 
| SARS COVID N Ab trends among different baseline PhenoAge scores | Hematology measure associated with PhenoAge scores | 6 month | 
| SARS COVID N Ab trends among different baseline PhenoAge scores | Hematology measure associated with PhenoAge scores | 9 month | 
| SARS COVID N Ab trends among different baseline PhenoAge scores | Hematology measure associated with PhenoAge scores | 12 month | 
| SARS COVID S Ab trends among different baseline PhenoAge scores | PhenoAge scores relation physiology measure | baseline | 
| SARS COVID S Ab trends among different baseline PhenoAge scores | Hematology measure associated with PhenoAge scores | 3 month | 
| SARS COVID S Ab trends among different baseline PhenoAge scores | Hematology measure associated with PhenoAge scores | 6 month | 
| SARS COVID S Ab trends among different baseline PhenoAge scores | Hematology measure associated with PhenoAge scores | 9 month | 
| SARS COVID S Ab trends among different baseline PhenoAge scores | Hematology measure associated with PhenoAge scores | 12 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SARS-CoV-2, Neutralizing antibody, Spike antibody, Cognitive function, long-COVID, Vaccine efficacy